Therapeutic Plasma Concentrations of Human Factor IX in Mice after Gene Delivery into the Amniotic Cavity: A Model for the Prenatal Treatment of Haemophilia B

Journal of Gene Medicine

Volumn 1, Issue 6, 1999, Pages 424-432

  Schneider, Holm ^a,b   Adebakin, Sheri ^a   Themis, Michael ^a   Cook, Terry ^c   Douar, Anne Marie ^d   Pavirani, Andrea ^e   Coutelle, Charles ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d GÉNÉTHON   (France)

^e TRANSGENE S A   (France)

Author keywords

Gene therapy; Haemophilia; In utero; Mouse model

Indexed keywords

BACTERIA (MICROORGANISMS); RODENTIA;

BLOOD CLOTTING FACTOR 9; HYBRID PROTEIN;

ADENOVIRUS; AMNION FLUID; ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS BLOOD; FETUS DEATH; FETUS DISEASE; GENE THERAPY; GENE VECTOR; GENETICS; HELA CELL; HEMOPHILIA B; HUMAN; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; NEWBORN; PRENATAL CARE; PRENATAL DEVELOPMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; TIME; VIROLOGY;

ADENOVIRIDAE; AMNIOTIC FLUID; ANIMALS; ANIMALS, NEWBORN; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR IX; FETAL BLOOD; FETAL DEATH; FETAL DISEASES; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HEMOPHILIA B; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PRENATAL CARE; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; TIME FACTORS;

EID: 0033222971     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-2254(199911/12)1:6<424::aid-jgm70>3.0.co;2-q     Document Type: Article

References (57)

1. Coutelle C, Douar AM, Colledge WH, Froster U. The challenge of fetal gene therapy. Nat Med 1995; 1: 864-866.
2. Schneider H, Coutelle C. In utero gene therapy: The case for. Nat Med 1999; 5: 256-257.
3. Setoguchi Y, Jaffe HA, Danel C, Crystal R. Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors. J Invest Dermatol 1994; 102: 415-421.
4. Fenjves ES. Approaches to gene transfer in keratinocytes. J Invest Dermatol 1994; 103: 70S-75S.
5. Greenhalgh DA, Rothnagel JA, Roop DR. Epidermis: an attractive target tissue for gene therapy. J Invest Dermatol 1994; 103: 63S-69S.
6. Khavari PA. Gene Therapy for genetic skin disease. J Invest Dermatol 1998; 110: 462-467.
7. DeLuca M, Pellegrini G. The importance of epidermal stem cells in keratinocyte-mediated gene therapy. Gene Ther 1997; 4: 381-383.
8. Douar AM, Adebakin S, Themis M, et al. Foetal gene delivery in mice by intra-amniotic administration of retroviral producer cells and adenovirus. Gene Ther 1997; 4: 883-890.
9. Gerrard AJ, Hudson DL, Brownlee GG, Watt FM. Towards gene therapy for haemophilia B using primary human keratinocytes. Nat Genet 1993; 3: 180-183.
10. Alexander MY, Bidichandani SI, Cousins FM, et al. Circulating human factor IX produced in keratin-promoter transgenic mice: a feasibility study for gene therapy of haemophilia B. Hum Mol Genet 1995; 4: 993-999.
11. Fenjves ES, Schwartz PM, Blaese RM, Taichman LB. Keratinocyte gene therapy for adenosine deaminase deficiency: a model approach for inherited metabolic disorders. Hum Gene Ther 1997; 8: 911-917.
12. Themis M, Schneider H, Kiserud T, et al. Successful expression of β-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein. Gene Ther 1999; 6: 1239-1248.
13. Smith TA, Mehaffey MG, Kayda DB, et al. Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
14. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-119.
15. Ferkol T, Lindberg GL, Chen J, et al. Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer. FASEB J 1993; 7: 1081-1091.
16. Fang B, Eisensmith RC, Wang H, et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-1044.
17. Baru M, Axelrod JH, Nur I. Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice. Gene 1995; 161: 143-150.
18. Walter J, You Q, Hagstrom JN, et al. Successful expression of factor IX following repeat administration of an adenoviral vector in mice. Proc Natl Acad Sci USA 1996; 93: 3056-3061.
19. Koeberl DD, Alexander IE, Halbert CL, et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 1997; 94: 1426-1431.
20. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
21. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5: 64-70.
22. Palmer TD, Thompson AR, Miller AD. Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. Blood 1989; 73: 438-445.
23. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A 1991; 88: 4626-4630.
24. Lozier JN, Thompson AR, Hu PC, et al. Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes. Hum Gene Ther 1994; 5: 313-322.
25. Brauker J, Frost GH, Dwarki V, et al. Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents. Hum Gene Ther 1998; 9: 879-888.
26. Dai Y, Roman M, Naviaux RK, Verma IM. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A 1992; 89: 10892-10895.
27. Yao SN, Kurachi K. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc Natl Acad Sci U S A 1992; 89: 3357-3361.
28. Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995; 92: 1401-1405.
29. Herzog RW, Hagstrom JN, Kung SH, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997; 94: 5804-5809.
30. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
31. Yao SN, Wilson JM, Nabel EG, et al. Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B. Proc Natl Acad Sci U S A 1991; 88: 8101-8105.
32. Cherington V, Chiang GG, McGrath CA, et al. Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion. Hum Gene Ther 1998; 9: 1397-1407.
33. Schnieke AE, Kind AJ, Ritchie WA, et al. Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science 1997; 278: 2130-2133.
34. White SJ, Page SM, Margaritis P, Brownlee GG. Long-term expression of human clotting factor IX from retrovirally transduced primary human keratinocytes in vivo. Hum Gene Ther 1998; 9: 1187-1195.
35. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992; 90: 626-630.
36. Graham FL, Eb AJvd. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-457.
37. Chartier C, Degryse E, Gantzer M, et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805-4810.
38. Graham FL, Smiley J, Russel WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-72.
39. Iwamoto HS, Trapnell BC, McConnell CJ, et al. Pulmonary inflammation associated with repeated prenatal exposure to an E1, E3-deleted adenoviral vector in sheep. Gene Ther 1999; 6: 98-106.
40. Meng X, Sawamura D, Tamai K, et al. Keratinocyte gene therapy for systemic diseases. J Clin Invest 1998; 101: 1462-1467.
41. Kaplan JM, Pennington SE, St George JA, et al. Potentiation of gene transfer to the mouse lung by complexes of adenovirus vector and polycations improves therapeutic potential. Hum Gene Ther 1998; 9: 1469-1479.
42. Holzinger A, Trapnell BC, Weaver TE, et al. Intraamniotic administration of an adenoviral vector for gene transfer to fetal sheep and mouse tissues. Pediatr Res 1995; 38: 844-850.
43. Baldwin HS, Mickanin C, Buck C. Adenovirus-mediated gene transfer during initial organogenesis in the mammalian embryo is promoter-dependent and tissue-specific. Gene Ther 1997; 4: 1142-1149.
44. Loeser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFκB. J Virol 1998; 72: 180-190.
45. Harris DT, Schumacher MJ, Locascio J, et al. Phenotypic and functional immaturity of human umbilical cord blood T-lymphocytes. Proc Natl Acad Sci U S A 1992; 89: 10006-10010.
46. Hunt DW, Huppertz HI, Jiang HJ, Petty RE. Studies of human cord blood dendritic cells: evidence for functional immaturity. Blood 1994; 84: 4333-4343.
47. Bradstock K, Luxford C, Grimsley P. Functional and phenotypic assessment of neonatal human leukocytes expressing natural killer cell-associated antigens. Immunol Cell Biol 1993; 71: 535-542.
48. Dominguez E, Madrigal JA, Layrisse Z, Cohen SBA. Fetal natural killer cell function is suppressed. Immunology 1998; 94: 109-114.
49. Silverstein AM, Parshall CJ, Uhr JW. Immunologic maturation in utero: kinetics of the primary antibody response in the fetal lamb. Science 1966; 154: 1675-1677.
50. Billings PR. In utero gene therapy: The case against. Nat Med 1999; 5: 256-257.
51. Wang L, Zoppe M, Hackeng TM, et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A 1997; 94: 11563-11566.
52. Lin HF, Maeda N, Smithies O, et al. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-3966.
53. Kundu RK, Sangiorgi F, Wu LY, et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood 1998; 92: 168-174.
54. Vailly J, Gagnoux-Palacios L, Dell'Ambra E, et al. Corrective gene transfer into keratinocytes from patients with junctional epidermolysis bullosa restores assembly of hemidesmosomes in reconstructed epithelia. Gene Ther 1998; 5: 1322-1332.
55. Braun-Falco M, Doenecke A, Smola H, Hallek M. Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors. Gene Ther 1999; 6: 432-441.
56. Feng M, Jackson WH, Goldman CK, et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 1997; 15: 866-870.
57. Caplan NJ, Higginbotham JN, Scheel JR, et al. Adeno-retroviral chimeric viruses as in vivo transducing agents. Gene Ther 1999; 6: 454-459.